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Solid State Ionic materials and devices are being used in medicine in many ways.  A  
brief initial introduction to the materials, the devices and the pertinent 
electrophysiological and clinical aspects is presented.  To exemplify the breadth of SSI 
material and device applications, an overview is given of three main areas:  Biomedical 
applications of solid state power sources;  Biofuel cells; and Iontophoretic and related 
devices used for controlled transdermal drug delivery and monitoring of physiological 
parameters 
. 




The importance of electrochemistry in facilitating and controlling the passage of ions 
in living tissues is universally acknowledged. Without redox reactions taking place within 
the body, life as we know it would cease. Electrochemistry also causes the production and 
storage of electrical energy from chemical reactions in power sources such as batteries and 
fuel cells.  
  
Advances in solid state ionics applications have required painstaking and careful 
materials development over the past forty years.  Medical applications of power sources and 
of their component materials impose their own strict requirements and constraints on device 
and material selection and often involve highly miniaturised systems.  The interdependence 
of the requirements of the solid state ionics and medical fields is shown schematically in 
figure 1.  In this paper, three particular areas at different stages of maturity - biomedical 
power sources, biofuel cells and iontophoretic devices - have been chosen to illustrate 
present and future applications of solid state ionic devices and their component materials in 
medicine. 
Solid State batteries are well suited to medical applications as they are inherently 
compact, robust, well encapsulated and spill-proof and can be implanted safely within the 
body to ensure long term stability and availability of power.  Applications up to the early 
part of this decade have been reviewed elsewhere [1]; more recent advances are described 
in section 2. 
 As diagnostic medicine advances, there is an increasing need for sensors that can 
transmit signals from within the part of the body that is malfunctioning.  Such sensors 
require a power source to be connected to them in order to function.  Connection by wire to 
the sensor is usually impossible without impeding the normal functioning of the patient’s 
body.  Wireless supply of sufficient power cannot be achieved at present without 
interference with normal bodily functions.   Consequently ultra-miniaturised biofuel cells 
are now being studied which can actually reside within the tissue or organ that is affected.  
Such fuel cells need to be supplied by reactants such as oxygen and glucose, which are 
physiologically available form the immediate environment.  The development of biofuel 
cells builds on earlier work on biosensors and other devices using biocatalysis and 
substantial progress is being made in this fast moving field [2-4].  For clarity, biofuel cells 
are described as microbial if living cells are involved and as enzymatic if they are not.  
  
Applications of microbial cells are reviewed elsewhere [5].  Section 3 focuses on medical 
applications of enzymatic fuel cells.   
Some electrolyte materials used in polymer solid state batteries can be modified to 
provide the drug reservoir in a particular type of medical drug delivery system known as an 
iontophoretic device.  This is externally mounted on the skin and the drug, which has to be 
ionic for this application, is driven into the bloodstream transdermally by the application of 
a voltage from an external power source.  Developments of a range of iontophoretic and 
related devices have been discussed elsewhere [6, 7] and recent advances are outlined in 
section 4. 
2. Medical Applications of Solid State Power Sources 
External or implanted power sources such as batteries and fuel cells are used in a 
variety of ways in medicine [1], including motorised wheelchairs; surgical tools; cardiac 
pacemakers and defibrillators; dynamic prostheses; sensors and monitors for physiological 
parameters; neurostimulators; devices for pain relief; and iontophoretic, electroporative and 
related devices for drug administration. It is helpful to separate applications into two 
categories by location of the power source.  External devices are those which are connected 
to the patient by wire.  In some cases the power source can be attached or transdermal, i.e. 
external to the body but located on the skin.  By contrast, implanted devices are located 
within the body.  
 In some cases such as that of the heart pacemaker battery, the implanted power 
source is situated remotely, i.e. at a different location from that of the device which it 
powers [8].  In others, such as planned autonomous sensor-transmitters powered by ultra-
miniature fuel cells, the power source will be attached to the device [4]. 
 
  
2.1 EXTERNAL APPLICATIONS 
Some applications such as motorized wheelchairs and some battery powered surgical 
implements have power requirements which are too large to be met by solid state devices 
[1].  There are other cases, e.g. left ventricular assist devices used for patients awaiting 
heart transplants, where a substantial power requirement is met by a combination of 
external and implanted batteries [8].   
Prototype devices are being developed to take over the functions of the semicircular 
canals in the ear, which act as physiological rotation sensors to preserve balance.  They use 
piezoelectric vibrating gyroscopes to measure the angular velocity of the head.  Pt 
electrodes are powered by Li batteries which, together with the sensors and computerised 
frequency converters are mounted externally [9].  A variety of sensors and monitors such as 
glucose sensors for diabetics and “halter” monitors storing electrocardiogram signals are 
powered by external batteries at present [8].  In the future, many of these may be developed 
to utilise miniaturised and implanted fuel cells [4] to provide “real time, true location” 
signal detection. 
Electric shocks from torpedo fish were used in ancient Greece to treat gout and the 
first example of the use of an electric current to increase penetration of ionic drugs into and 
through surface tissue was in 1747 [7]. The term iontophoresis was introduced for this 
process in the 19th century [10].  A variety of power sources has been used for iontophoresis 
[6, 7, 11, 12] and for related processes such as  electroporation [13].  External power 
sources have also been used to control drug delivery from implantable reservoirs [1] in 
order to improve patient compliance with a given therapy,  the relative ease of self-dosing 
eliminating the need for multiple intravenous injections [14].   
Power sources for transdermal devices for iontophoresis and related processes can 





2.2 IMPLANTED  POWER SOURCES 
  Monitoring the responses of individuals to drugs and other stimuli is very important 
as drugs are presently administered at frequencies and doses based on averages which have 
been optimised for large, often heterogeneous, populations.  Individual behaviour differs, 
either permanently or temporarily, from the average and it is therefore desirable to have 
individualised, integrated medical systems comprising implanted sensors, batteries, 
amplifier, processor and actuator for such applications as heart pacemakers and 
defibrillators [15]. 
Most implanted power sources are located remotely from the device they power.  
Neurostimulators for pain relief, tremour reduction in Parkinson’s disease [1], incontinence 
[16] and epilepsy [17] also have a power demand within the range of implanted batteries. 
Recent studies have investigated the possible interaction between such devices and the high 
magnetic fields used in MRI scanning [18]. 
The largest application of remote, implanted batteries, however, is the heart 
pacemaker in which the Li battery is located below the skin between the shoulder and the 
neck and is connected to electrodes in the heart muscle [19].  The heart pacemaker was 
initially developed in 1959 [20] and the first that was powered with a Li battery was 
implanted in 1972 [21].  It is designed to assist in bradycardia, an illness where the heart 
beats too slowly.  A similar device, the implantable cardiac defibrillator, addresses 
tachycardia, a medical condition where the heart beats too quickly [22] and which, if 
untreated, can degenerate into ventricular fibrillation and death. 
An example of a power source directly attached to an implanted device, which is 
currently undergoing clinical trials is a fully implanted hearing aid using pacemaker-type 
batteries integrated with the rest of the device and located just behind the ear [23].  Perhaps 
  
the most exciting future development, hopefully to be realised soon, is implantable sensor-
transmitter systems, smaller than 1 mm3 powered by integral glucose – oxygen biofuel cells 
[4]. 
 
2.3 TYPES OF SOLID STATE POWER SOURCES USED IN MEDICINE 
Li / Silver vanadium oxide (SVO) batteries are used, in conjunction with stacked plate 
aluminium electrolytic capacitors, to power implantable cardioverter-defibrillators.  The 
electrode balance needs to be carefully optimised [24].  Alternative systems include Li / 
CFx and Li / MnO2 (MDX) [25].  The Li / I2-PVP primary battery is the system of choice for 
low rate applications such as pacemakers [26, 27].  Implantable Li Ion batteries have been 
used in test systems for undulation pump total artificial hearts [28].  Potential 
nanobiotechnological devices including molecular motors and artificial organs and their 
power sources have recently been reviewed [29].  Optimisation studies are being carried out 
to facilitate future implantable fuel cells [30] and systems involving chitosan (extracted 
from shellfish shells, one of the world’s largest sources of discarded materials) are also 
being proposed for implanted batteries [31].  Dangers accompanying the use of batteries in 
medicine have recently been reviewed elsewhere [1]. 
 
3. Enzymatic Biofuel Cells 
Batteries and fuel cells are both electrochemical devices in which electrons move 
through an external circuit where they can do electrochemical work and the charge 
compensating ions move from one electrode to another through an electrolyte membrane.  
In the former, the electrode material cannot be replenished (although in rechargeable or 
secondary batteries, the ions can be sent back to the electrodes from which they came) 
whereas in the latter, the electrode fuel, usually gaseous or liquid, can be continuously 
  
supplied and is catalytically converted to active electrode material, usually by a precious 
metal catalyst. 
  A biological fuel cell or biofuel cell is a hybrid of fuel cell technology and 
biotechnology and the catalysts are enzymatic, either contained in microorganisms or as 
isolated proteins.  There was a particular interest in the USA in the 1960s in developing 
biofuel cells as energy-saving, waste disposal systems for extended space flights [32].  
Biofuel cells cannot approach the performance of conventional systems.  Platinum based 
hydrogen – air and methanol fuel cells can achieve 1 A/cm2 and 0.65V and 0.5 A/cm2 and 
0.5V respectively whereas the best methanol-air biofuel cells produce less than 10 m A/cm2 
[33]. 
The focus in this paper is on biofuel cells for medical use (often in miniaturized 
form), powered by physiologically available reactants and used for diagnostic and related 
applications.  Biofuel cells are similar to biosensors and other devices which use enzymatic 
biocatalysis although biocatalysed sensors are often inexpensive enough to be disposable, 
so stability for sensors is not a major issue.  Bioelectrocatalysts form molecular transducers 
which convert chemical into electrical signals [2].   
  Biofuel cells are described as microbial if living cells are involved and as enzymatic 
if they are not; see figure 3.  A further distinction is between direct and indirect biofuel 
cells.  In the former, fuel is oxidised at the surface of the electrode in an enzymatically 
catalysed reaction whereas in the latter, the fuel reacts in solution or in a separate 
compartment and a redox active mediator shuttles electrons between the reaction site and 
the electrode.  Often, enzymes are used in direct fuel cells and microorganisms in indirect 
configurations [32]. 
Maximising Vcell and  Icell so that power and energy output are as large as possible 
represent key challenges to biofuel cell development.  For a direct fuel cell, Vcell is the 
  
difference between the potentials of the fuels, corrected for overpotentials (which are non-
trivial and reflect the effects of slow kinetics of heterogeneous electron transfer, ohmic 
resistances and concentration gradients).  For an indirect cell, Vcell is the difference between 
the mediator potentials, again corrected for overpotentials [5].  Icell is influenced by such 
factors as electrode size, rate of electrode processes and rate of ion transport across the 
electrolyte membrane.  Power lost to irreversible processes usually appears as heat, the 
management of which is vital in biofuel cells as enzymes are very temperature sensitive 
[32]. 
The most common cathodic fuel for biofuel cells is O2, being readily available with a 
harmless reaction product (water).  It is thermodynamically a good oxidant although 
kinetically it is poor.  ABTS (2,2’-azinobis(3-ethylbenzothiazoline-6-sulphonate) has been 
used as a cathodic mediator to facilitate diffusion processes [2].   
For conventional fuel cells, typical anodic fuels are H2, methane, natural gas, gasoline, 
diesel fuel or methanol but for biofuel cells reactions involving fuels such as glucose, which 
are present in the bloodstream, are of particular interest.   The common cofactor or anode 
mediator of choice is nicotinamide adenine dinucleotide (NAD+) which is reduced by the 
fuel to NADH and subsequently reoxidised to continue the enzymatic reaction. Over 60% 
of the oxidoreductases listed in Enzyme Nomenclature have NAD+ or its phosphorylated 
equivalent NADP+ as reactant or product [2].  The standard electrode potential is -0.32V at 
pH 7.0 with respect to the normal hydrogen electrode (-0.62V vs. SCE at pH 7.5) but in 
practice, because activities are not unity, there is a 1V overpotential which requires to be 
minimised if practical biofuel cells are to be achieved. 
It can be desirable to contain the enzymes and electron transfer mediators within a 
small volume to maximise concentration and activity.  Membranes cause an unacceptable 
restriction in diffusional flux and so immobilisation of the active species on a surface, or 
  
within a tethered polymer brush or network is preferred [2].  Similar issues are encountered 
in the design of polymer electrolyte materials for flexible battery applications [6]. 
Enzymes are not only efficient catalysts; they are also very selective.  An upper rate 
limit for enzyme catalysis is around 100 Coulombs per minute from 1 mg of enzyme, i.e. 
about 1.6A.  In practice, however, allowing for practical specific activities, 1mA is more 
realistic [32].   
The issues involved in using entire microorganisms in fuel cells have been well 
reviewed elsewhere [5].  In these microbial fuel cells bacteria such as clostridium butyricum 
can lead to the production of hydrogen from the fermentation of glucose by a more 
complicated pathway than is needed for enzymatic fuel cells.  In bacteria, glucose is 
converted to pyruvate and NADH by the Embden-Meyerhof pathway.  The pyruvate is then 
oxidised with ferredoxinox oxidoreductase to produce acetyl – CoA together with CO2 and 
ferredoxinred .  At the same time, the NADH also reacts with ferredoxinox  to produce NAD+ 
and ferredoxinred .  The ferredoxinred produced by both routes reacts with protons in the 
presence of hydrogenase to form H2.  Ideally 4 mol of H2 would be produced from 1 mol of 
glucose but in practice the yield is only a quarter of this[5]. 
In enzymatic fuel cells, the demanding operating conditions required to ensure the 
continuous fermentation of  whole living cells are replaced by different, but no less 
stringent, requirements to ensure the stabilisation and efficient utilisation of sensitive and 
expensive enzymes.  Just as batteries can be used in medicine either as implanted or 
external devices, enzymatic fuel cells can be developed as external power sources or as 
miniaturised, implantable devices.  For external applications for potential medium power 
applications, a mediated approach has to be used because redox enzymes cannot directly 
transfer electrons to the electrodes; their redox centres are insulated by the protein matrices 
that surround them.  A variety of possible approaches have been developed by Willner and 
co-workers [5]. 
  
The most promising area for medical applications of biofuel cells is as implantable 
power sources for macro-scale (e.g. heart pacemaker) or micro-scale (e.g. in-situ, 
diagnostic, integrated, miniaturised, self-powered sensor) applications. 
 
3.1 MACRO DEVICE APPLICATIONS 
  Natural biocatalysts are physiological species which have adapted to optimise their 
functioning in complex physiological environments at physiological temperature (~ 37 0C) 
and near neutral pH (~7).  They utilise naturally occurring fuels and oxidants and produce 
reaction products that the host can tolerate.  All these features are promising for potential 
implantable applications as biocatalytic coated electrodes need not be sealed off from 
physiological fluids.  This is just as well because the price of achieving stability by using 
protective barrier membranes would be to reduce reactant mass transfer.  Typical reactants 
are already present in rather low concentrations (glucose, 5mMol/L; oxygen 0.1 mMol/L; 
lactate 1 mMol/L) and maximum current density is therefore limited by the ability of such 
reactants to diffuse into the bioelectrodes.  In the case of electrodes situated in blood vessel 
walls, transport can be enhanced by blood flow (typically 1 to 10 cm/s).  The flux of 
glucose has been calculated to be only about 1 mA/cm2 [2] and rates would be even lower 
in tissue.  
Heart pacemakers and a variety of other implanted devices were described in section 
2.2.  At present the lifetime of a 1 Wh/mL battery with a typical operating regime of 1 µW 
exceeds 10 years which suffices for pacemaker applications.  The best biofuel cell operating 
today can just achieve one-hundredth of this energy density, giving a lifetime measured in 
days.  Potentially, however, if glucose from the body is used as fuel and oxygen dissolved 
in body fluids is the oxidant, the implantable biofuel cell could achieve high power density 
and infinite energy density [2]. 
  
  Damage is caused by the implantation process, especially into blood vessels where 
clotting is a hazard.  Here the surgical procedures are worthwhile only if the cell itself is 
stable and benign enough to survive more than a year, whereas in tissues shorter lifetimes 
may still confer benefit.  Another risk issue for tissues is the toxicity of the implanted cell 
components.  Many of the relevant enzymes have received GRAS (generally recognised as 
safe) recognition from the US Food and Drug Administration [34].  Mediators sometimes 
involve osmium compounds, certain of which are considered as toxic although others have 
been used for treatment of arthritis [35] and haemophilia [36].  It is suspected that, whereas 
concentrations involved in manufacture may be hazardous, toxicity at in vivo concentrations 
may be low [37].  
The range of difficulties outlined above means that, even at the present day, the 
majority of enzyme fuel cells actually involve only one bioelectrode, coupled with a noble 
metal counter electrode [2].  True biofuel cells involving two enzyme electrodes are still 
either limited to levels of performance below those which would be useful (e.g. 5 µW/cm2) 
for implantable applications, or which are microbial rather than enzymatic [2].  A key 
problem is to achieve two electrodes both working at the physiological pH value of 7.  This 
has been achieved in a methyl viologen mediated bacterial cell in which both electrodes had 
carbon felt sheets immersed in pH 7 phosphate buffer with freely diffusing catalysts and 
mediators, the two compartments being separated by an anion exchange membrane.  The 
voltage was adequate at 1.17V and the current density was 0.45 mA/cm2 but the lifetime 
was unacceptably low at 2 hours [38]; the same team are also working on a 
compartmentless glucose – oxygen cell [39]. 
 
3.2  MICROSCALE DEVICES 
Heller [4] has recently reviewed the work of his team in developing miniature, low 
cost glucose – oxygen fuel cells to power autonomous sensor-transmitters designed for 
  
implantation in the tissue under study.  Their goal is to produce fuel cells smaller than 1 
mm3 , lighter than 100 µg and costing less than 1$ to power autonomous sensor – 
transmitter packages broadcasting several types of information.  Local tissue temperature 
enables inflammation to be monitored.  Local pressure in particular blood vessels or other 
fluid channels indicates possible fluid blockage which, together with the success of any 
steps taken for its release can be monitored.  A further parameter that can be monitored is 
any deviation from the normal concentration of a chosen chemical whose presence can be 
used to monitor the progress of a disease. 
The sensor is likely continuously to consume only about 1µW.  The remaining few 
µW produced by the miniature fuel cell are needed to charge a small ultracapacitor, capable 
of storing about 1 µJ which can produce 1 GHz bursts of 10mW, for 1 ms every 10s to 
power the transmitter [4] 
A number of prototype fuel cells have been built which are more than 100 times 
smaller than the smallest present day battery or fuel cell.  This size reduction has been 
achieved by eliminating seven of the nine components needed in conventional fuel cells.    
The redundant items are: the  plumbing to anode and cathode compartments as the cell is 
surrounded by its fuel dissolved within the ambient body fluids; an external case and case 
seal, designed to encapsulate the cell components and prevent leakage into the environment; 
and a membrane and seal providing a sealed matrix for the ion conducting electrolyte. 
A conventional fuel cell using a platinum group metal as catalyst has to incorporate a 
membrane because the catalyst is capable of promoting not only the desired oxidation of the 
fuel but also the highly undesirable reduction of O2  and a compartment-separating 
membrane is needed to prevent this.  Incidentally, many early glucose – electrooxidising 
cells also required a membrane because the platinum metal catalysts at their O2 electrodes 
were fouled by the glucose electrooxidation products.  The selectivity of enzyme based 
catalysts means that undesirable side reactions are not promoted and compartment isolation 
  
becomes unnecessary [4].  The classic development that led to biofuel cells without 
membranes was when Willner and co-workers used immobilised bioelectrocatalysts, their 
enzymes being  “wired” to electrodes through electronically conducting hydrogels, to 
catalyse either glucose oxidation at the anode or O2 reduction at the cathode but not vice 
versa [40].  
An early design involved enzymatic electrodes immobilised within, and mediated by, 
osmium-based redox hydrogels deposited on 7 µm diameter carbon fibres.  At present, the 
cell operates at pH 5 in a citrate buffer saturated with air and containing 15 mMol/L of 
glucose and produces 340 µA/cm2 and 0.4V at 37 oC.  Current density decreases by 8% a 
day because of limitations in anode performance [2].   The pH is too far from the 
physiological level, the redox potential of the anode mediator is too high and the deposited 
hydrogel film is too thick to permit rapid electron transport.  A variant on this design uses 
an anode mediator with a lower redox potential and a cathode catalyst that functions at pH 7 
[41].  The voltage is 0.52 V and the current density is 340 µA/cm2, thus more than doubling 
the power density achieved.  The stability, however, is only marginally better at 6% current 
density loss per day.  Recent developments are summarised by Heller [4].  Barton and 
colleagues have discussed [2] the key issues that need to be addressed for implanted biofuel 
cells to be widely adopted – biocompatibility; better activity and stability (achieved by 
engineering both the protein molecule and its environment, perhaps by biomimetics [42]); 
increased current density; improved mediators and / or better immobilisation using 
controlled nanoporous substrates; extended device lifetimes; greater power (mW to W scale 
in blood vessels and µW in tissue); and better integration with electrical devices, including 
multi power source stacks. Solving these problems requires the same type of multi-
disciplinary approach (from chemists, chemical engineers, materials scientists and, of 
course, biologists) as was needed to launch the field of solid state ionics.   
  
4. Iontophoretic and Related Devices 
There are many routes, each with its own advantages and limitations, that can be 
chosen to convey a drug from outside the patient to the physiological site of action within 
the body [6].  For example, many drugs can be taken by mouth (perhaps encapsulated in an 
appropriate excipient) but the oral route is unsuitable for strong tasting substances.  More 
importantly, some drugs cannot survive in the required active form when they enter the 
body through the relatively destructive digestive tract, and others have adverse effects on 
the digestive processes.  There is also a cycling effect associated with regular oral delivery, 
shown in fig 2.   
In such cases, one of a number of alternative pathways needs to be chosen [7].  These 
include insertion of a suppository or a catheter into an orifice other than the mouth; 
injection from a syringe that penetrates through the skin into a muscle or a vein; inhalation, 
either nasally or orally, of a drug carried either in wet droplets or as dry powder in a carrier 
gas, into  the lung (which has a very large internal surface area); topically, i.e. by external 
application of ointments containing volatile active drug which diffuses into the eye, tooth, 
nail or skin to relieve chafes, scratches, cuts and bites;  transdermally, by dry powder 
syringe which itself does not penetrate the skin but which projects the drug material into the 
subcutaneous layers below; transdermally by “passive device” patches, e.g. nicotine worn 
by smokers trying to give up, which act as a local reservoir of an appropriate drug which 
permeates through the skin to the site of action unaided by additional fields or forces other 
than diffusion; transdermally, assisted electrically (i.e. iontophoretically) and/or in  other 
ways. 
Non-invasive routes minimise the chances of cross infection especially by the AIDS 
virus. 
  
Skin is one of the largest of the bodily organs, covering 2 m2, weighing 5 kg and being 
2-3 mm thick.  There are two key parts – the outer layer (epidermis) and the inner layer 
(dermis), between which there is a basement membrane.  The most important layer within 
the epidermis is the stratum corneum, a 10-15 µm thick lipophilic barrier that minimizes 
transepidermal water loss, acts as a high-integrity barrier against egress of foreign material 
and has a high electrical resistance. The equivalent circuit is essentially the same as that for 
a polymer electrolyte as the stratum corneum has a high electrical resistance, in series with 
the dermis, which comprises a leaky capacitor (constant phase element) and a resistor in 
parallel.   The stratum corneum is dry (20% moisture compared with 70% for most of the 
rest of the body).  Penetrating through the epidermis and providing a path from the outside 
world to deep within the dermis are hair follicles and pores which, in human skin, take up 
only about 0.1% of the surface area.  The pH of the stratum corneum is 4 –6, being lowest 
just below the surface, whereas the hydrated tissue just under the basement membrane has a 
pH of about 7.3.   
The history of iontophoresis has been described elsewhere [6, 7, 12].  Iontophoretic 
devices are in 3 parts – a power source providing up to 4mA at constant current 
(corresponding to a 8 cm2 patch delivering the maximum desirable current density of 0.5 
mA/cm2) which, in the future, could well be a polymer electrolyte battery – a drug electrode 
which provides the reservoir of active ingredient – and an “indifferent” (or ground or 
dispersive) electrode [43, 44].  The reservoir can be made from materials analogous to the 
polymer electrolytes originally developed by Michel Armand [45-47].  Sensor control of 
drug flux is very desirable and an impedance-based implantable microelectromechanical 
system (MEMS) device has recently been reported [48].  Drug penetration can be enhanced 
by chemical penetration enhancers such as PPG [49] or by sonophoresis  using 
ultrasound[50].   
  
There is a range of techniques related to iontophoresis [6, 11].   Electroporation can be 
used to deliver DNA into cells and allow transdermal delivery of non-ionic drugs [51].  
Reverse iontophoresis is used for non-invasive sampling of glucose and other blood 
constituents [52].  Iontophoresis can be used to treat hyperhidrosis or excess sweating, 
although “botox” has been found to be more successful [53].   A range of drugs can usefully 
be delivered by iontophoresis including lidocaine for local anaesthesia, cisplatin for basal 
cell carcinoma, vasopressin as an anti-diuretic and salmon calcitonin to control post-
menopausal osteoporosis 6, 11].  Analogues of polymer electrolyte materials prepared for 
conventional solid state ionic devices have been shown to be suitable as iontophoretic 
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Figure Captions 
Fig. 1: Schematic relationship between solid state ionics and medicine 
Fig. 2: Time course of drug level following oral administration of conventional dosage 
forms compared to a long-acting, e.g. iontophoretic delivery system (MTC: minimum 
toxic concentration; MEC: minimum effective concentration). 
Fig. 3:   Schematic diagram of examples of: a) a microbial bioreactor supplying fuel 
inside the anodic compartment of an electrochemical cell; b) an enzymatic biofuel half 
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